期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Current systems and recent developments of subthreshold laser systems in glaucoma:a narrative review
1
作者 Amrish Selvam Joshua Ong +2 位作者 Rajesh S.Kumar Jay Chhablani Dmitrii S.Maltsev 《Annals of Eye Science》 2022年第3期38-54,共17页
Background and Objective:Subthreshold laser technologies and their applications in ophthalmology have greatly expanded in the past few decades.Initially used for retinal diseases such as central serous chorioretinopat... Background and Objective:Subthreshold laser technologies and their applications in ophthalmology have greatly expanded in the past few decades.Initially used for retinal diseases such as central serous chorioretinopathy and diabetic macular edema,subthreshold lasers have recently shown efficacy in the treatment of various types of glaucoma.Our primary objectives are to review the clinical applications of subthreshold laser in the context of glaucoma treatment and discuss the mechanisms of different subthreshold laser techniques,including subthreshold selective laser trabeculoplasty(SSLT),micropulse laser trabeculoplasty(MLT),pattern-scanning laser trabeculoplasty(PSLT),titanium laser trabeculoplasty(TLT),and micropulse transscleral cyclophotocoagulation(MP-TSCPC).Methods:This was a narrative review compiled from literature of PubMed and Google Scholar.The review was performed from March 2021 to October 2021 and included publications in English.We also included information from web pages to cover details of relevant laser systems.We discuss the history of subthreshold laser,recent advancements in subthreshold techniques,and commercially available systems that provide subthreshold capabilities for glaucoma.We highlight basic science and clinical studies that deepen the understanding of treatment mechanisms and treatment effectiveness in the clinical setting respectively.We review commonly used parameters for each technique and provide comparisons to conventional treatments.Key Content and Findings:We found five distinct types of subthreshold laser used in the management of glaucoma.Numerous subthreshold laser systems are commercially available and can provide this treatment.Therefore,understanding the differences between subthreshold techniques and laser systems will be critical in utilizing subthreshold laser in the clinical setting.Conclusions:Traditional laser trabeculoplasty(LT)and cyclophotocoagulation(CPC)have shown effectiveness in the treatment of various types of glaucoma but are associated with visible damage to the underlying tissue and adverse effects.Subthreshold laser systems aim to provide the therapeutic effect found in traditional lasers,while minimizing unwanted treatment related effects.Further clinical studies are needed to evaluate the role of subthreshold lasers in the management of glaucoma. 展开更多
关键词 Subthreshold laser cyclophotocoagulation(CPC) micropulse laser laser trabeculoplasty(LT) GLAUCOMA
下载PDF
极高强度他汀治疗对冠状动脉粥样硬化消退的影响——ASTEROID试验 被引量:342
2
作者 Steven E. Nissen Stephen J. Nicholls +16 位作者 Ilks Sipahi Peter Libby Joel S. Raichlen Christie M. Ballantyne Jean Davignon Raimund Erbel Jean Charles Fruchart Jean-Claude Tardif Paul Schoenhagen Tim Crowe Valerie Cain Kathy Wolski Marlene Coormastic E. Murat Tuzcu 仝其广(译) 王淑敏(译) 胡大一(校) 《美国医学会杂志(中文版)》 2006年第4期215-223,共9页
背景:以前的血管内超声(intravascular ultrasound,IVUS)试验证实,他汀治疗可减缓或阻止动脉粥样硬化的进展,但是迄今尚无应用动脉粥样斑块体积百分比(percent atheroma volume,PAV)证实粥样硬化消退的确切证据。PAV是最严格... 背景:以前的血管内超声(intravascular ultrasound,IVUS)试验证实,他汀治疗可减缓或阻止动脉粥样硬化的进展,但是迄今尚无应用动脉粥样斑块体积百分比(percent atheroma volume,PAV)证实粥样硬化消退的确切证据。PAV是最严格的评价病变进展和消退的IVUS测量指标。 目标:评价极高强度他汀治疗是否能逆转IVUS确定的冠状动脉粥样硬化。 设计和地点:于美国、加拿大、欧洲和澳大利亚53个社区和3级保健中心进行前瞻性开标盲法终点试验(A Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound-Derived Coronary Atheroma Burden,ASTEROID)。应用马达驱动回撤IVUS评价基线和治疗24个月时冠状动脉粥样斑块负荷。每对基线和随访IVUS测量结果均进行盲法分析。 病例:从2002年11月到2003年10月,507例患者有基线IVUS检查结果,并接受至少1个剂量的研究药物。在24个月后,349例患者具有可用于评估的系列IVUS检查结果。 干预:所有患者均接受瑞舒伐他汀40ms/d强化治疗。 主要观测指标:预先设定了两个一级疗效指标:PAV变化和基线最严重病变10min节段动脉粥样斑块体积变化。二级疗效指标为整个动脉标准化总斑块体积的变化。结果:平均(SD)LDL—C水平由基线时的130.4(34.3)ms/dL降至60.8(20.0)ms/扎,平均下降了53.2%(P〈0.001)。平均(SD)HDL-C水平从基线时的43.1(11.1)ms/dL升至49.0(12.6)ms/dL,平均增加了14.7%(P〈0.001)。整个血管PAV平均(SD)变化为-0.98%(3.15%),中位数为-0.79%(97.5%CI,-1.21%~-0.53%)(与基线比较,P〈0.001)。最严重病变10min节段斑块体积平均(SD)变化为-6.1(10.1)mm^3,中位数为-5.6mm^3(97.5%CI,-6.8~-4.0mm^3)(与基线比较,P〈0.001)。总斑块体积变化中位数降低了6.8%,平均减少了-14.7(25.7)mm^3,中位数为-12.5mm^3(95%CI,-15.1~-10.5mm^3)(与基线比较,P〈0.001)。不良事件少见,与其他他汀试验相似。 结论:应用瑞舒伐他汀40ms/d进行极高强度他汀治疗可使LDL-C平均水平达到60.8ms/dL,使HDL—C增加14.7%。这导致所有3个预先设定的IVUS斑块负荷指标均显示动脉粥样硬化消退。因此,将LDL-C降至低于目前指南规定的水平,同时显著提高HDL-C,可以使冠心病患者动脉粥样硬化斑块消退。这些变化对临床预后的影响尚需进一步研究确定。 展开更多
关键词 冠状动脉粥样硬化 瑞舒伐他汀 强化治疗 斑块消退 冠状动脉粥样斑块 INTRAVASCULAR 试验 强度 ROSUVASTATIN 冠心病患者
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部